Wearable Technology to Reduce Sedentary Behavior and CVD Risk in Older Adults

NCT ID: NCT02632487

Last Updated: 2018-11-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

58 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-04-30

Study Completion Date

2018-11-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the feasibility and efficacy of combining a traditional, structured exercise intervention with an innovative intervention designed to decrease sedentary behavior and increase non-exercise physical activity (NEPA).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A recruitment of 40 sedentary men and women ≥ 60 years of age with elevated cardiovascular risk and follow them for 20 weeks. Participants will be randomly assigned (n = 20/group) to 1) an 8-week, twice-weekly, multi-modal, center-based exercise intervention (EX) followed by 12 additional weeks of follow-up assessment, or 2) the same intervention with participants also asked to wear a validated lightweight activity tracker on their hip during waking hours and instructed on how to reduce sedentary behavior increase NEPA within their daily routines (EX + NEPA). Evaluations will be done to 1) the extent to which EX + NEPA modifies sedentary behavior, 2) the impact of the interventions on cardiovascular risk factors, including blood pressure, exercise capacity, waist circumference, and circulating biomarkers, and 3) develop and optimize study procedures to guide the future trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exercise

This group will receive 8 weeks of center-based exercise followed by recommendations to remain physically active.

Group Type ACTIVE_COMPARATOR

Exercise

Intervention Type BEHAVIORAL

Center-based walking + balance, stretching, and light resistance

Exercise + Non-Exercise Physical Activity (NEPA)

This group will receive 8 weeks of center-based exercise combined with behavioral counseling and a technology intervention designed to increase daily Exercise + Non-Exercise Physical Activity (NEPA).

Group Type EXPERIMENTAL

Exercise

Intervention Type BEHAVIORAL

Center-based walking + balance, stretching, and light resistance

Non-Exercise Physical Activity (NEPA)

Intervention Type BEHAVIORAL

Behavioral counseling paired with technology intervention to monitor physical activity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exercise

Center-based walking + balance, stretching, and light resistance

Intervention Type BEHAVIORAL

Non-Exercise Physical Activity (NEPA)

Behavioral counseling paired with technology intervention to monitor physical activity

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Sedentary lifestyle, defined as \<150 min/wk of moderate physical activity by CHAMPS questionnaire
* Moderate to high-risk of CHD events according to ATP-III risk classification algorithm
* Willingness to be randomized to either intervention group
* Willingness to participate in all study procedures

Exclusion Criteria

* Failure to provide informed consent;
* Regular participation in an exercise training program within the last 3 months
* Absolute contraindication(s) to exercise training (American College of Sports Medicine guidelines)
* Office SBP \> 180 mm Hg or DBP \> 110 mm Hg
* Severe cardiac disease, i.e. NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina;
* Myocardial infarction or stroke within past year
* Significant cognitive impairment, i.e. known dementia or a Mini-Mental State Examination score \< 24
* Progressive, degenerative neurologic disease, e.g., Parkinson's Disease, multiple sclerosis, ALS;
* Severe rheumatologic/orthopedic disease, e.g., awaiting joint replacement, active inflammatory disease
* Severe pulmonary disease, requiring either steroid pills or injections or the use of supplemental oxygen;
* Hip fracture, hip or knee replacement, or spinal surgery within past 4 months;
* Other significant co-morbid conditions that would impair ability to participate in the intervention
* Simultaneous participation in another intervention trial
Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

American Heart Association

OTHER

Sponsor Role collaborator

University of Florida

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stephen Anton

Role: PRINCIPAL_INVESTIGATOR

Univesity of Florida

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UF Clinical Translational Research Building

Gainesville, Florida, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB201501139

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.